(11) **EP 1 637 152 A8** 

(12)

## **CORRECTED EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC Note: Bibliography reflects the latest situation

(15) Correction information:

Corrected version no 1 (W1 A1) INID code(s) 71

(48) Corrigendum issued on: 23.08.2006 Bulletin 2006/34

(43) Date of publication: **22.03.2006 Bulletin 2006/12** 

(21) Application number: 04729596.9

(22) Date of filing: 27.04.2004

(51) Int Cl.: **A61K 36/00** (2006.01)

(86) International application number: PCT/CN2004/000409

(87) International publication number: WO 2004/098623 (18.11.2004 Gazette 2004/47)

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 07.05.2003 CN 03130709

(71) Applicant: Li Min Pharmaceutical Factory of Livzon Pharmceutical Group Shaoguan Guangdong 512028 (CN)

(72) Inventors:

· XIE, Weihong

**Guandong Province 512028 (CN)** 

LIU, Xuehua

**Guangdong Province 512028 (CN)** 

· CHEN, Maoru

**Guandong Province 512028 (CN)** 

(74) Representative: Ebner von Eschenbach, Jennifer

et al

LADAS & PARRY LLP Dachauerstrasse 37 80335 München (DE)

## (54) A NOTOGINSENG SAPONIN INTRAVENOUS INJECTION AND THE METHOD FOR PREPARING THIS INJECTION

(57) The invention shows the saponins family of *Radix notoginshen* intravenous injection, a method for preparation thereof. The object is to provide an intravenous injection for prevention and treatment of cardiac and cerebral vascular disease and its sequelae. This injection has stable pH, could be used in large dosage, and with main active component of saponins family of *Radix notoginshen*. The main components for this injection includes saponins family of *Radix notoginshen* with a concentration of 0.1mg-14.0mg (RgI), iso-osmotic solution with a concentration of 7.5-9.6mg/mI, and pH stabilizer with a concentration of 0.2-0.5mg/mI. The solvent for said injection is distilled water. The method for preparation of the saponins family of *Radix notoginshen* intravenous injection includes: (1) dissolution of iso-osmotic solution in distilled water to a concentration of 50-300mg/mI, and filtration through active carbon; (2) addition of the saponins family of *Radix notoginshen* intravenous injection to the filtrate to a concentration of 0.1 mg-14.0mg (RgI); (3) addition of pH stabilizer to the filtrate to a concentration of 0.2-0.5mg/mI, filtration until clear, packaging and obtaining of the saponins family of *Radix notoginshen* intravenous injection.




Fig. 1